<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">BETHUNE-VOLTERS, ANNE</style></author><author><style face="normal" font="default" size="100%">LABROQUERE, MARC</style></author><author><style face="normal" font="default" size="100%">GUEPRATTE, SYLVIE</style></author><author><style face="normal" font="default" size="100%">HACENE, KAMEL</style></author><author><style face="normal" font="default" size="100%">NEUMANN, RAINER</style></author><author><style face="normal" font="default" size="100%">CARNEY, WALTER</style></author><author><style face="normal" font="default" size="100%">PICHON, MARIE-FRANCE</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Longitudinal Changes in Serum HER-2/&lt;em&gt;neu&lt;/em&gt; Oncoprotein Levels in Trastuzumab-treated Metastatic Breast Cancer Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1083-1090</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><issue><style face="normal" font="default" size="100%">2C</style></issue><abstract><style  face="normal" font="default" size="100%">Background: To evaluate longitudinal variations of serum HER-2/neu extracellular domain (sHER-2) in metastatic breast cancer patients receiving combined trastuzumab treatment. Patients and Methods: Thirty-three patients were monitored by serial sHER-2 ELISA (Oncogene Science). Results were compared to time to progression (TTP) and survival from treatment initiation. Non parametric statistical tests were used. Results: Median sHER-2 before first injection was 41.37 ng/ml (range 7.54-1597.00 ng/ml, n=32). Mean sHER-2 levels differed significantly between responders (n=20) and non responders (n=13) (p&lt;0.0001). Median TTP (266 days, range 35-1000 days) was unrelated to clinico-biological variables at diagnosis or number and site of metastases before treatment. Patients with pre-treatment sHER-2 levels ≤30 ng/ml (n=14) had a significantly longer TTP than the group with sHER-2 &gt; 30 ng/ml (n=18) (p=0.0346) and sHER-2 levels were of prognostic value for overall survival from first injection (p=0.0150). Conclusion: Our results show that monitoring serum HER-2/neu levels during metastatic breast cancer can provide a real time assessment of a woman's HER-2/neu status and can provide important information for therapeutic decisions. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>